Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

BACKGROUND & AIMS We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously reported genetic risk factors. METHODS We performed a GWAS of 862 persons with DILI and 10,588 population-matched controls. The first set of cases was recruited before May 2009 in Europe (n = 137) and the United States (n = 274). The second set of cases were identified from May 2009 through May 2013 from international collaborative studies performed in Europe, the United States, and South America. For the GWAS, we included only cases with patients of European ancestry associated with a particular drug (but not flucloxacillin or amoxicillin-clavulanate). We used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. After the discovery analysis was concluded, we validated our findings using data from 283 European patients with diagnosis of DILI associated with various drugs. RESULTS We associated DILI with rs114577328 (a proxy for A*33:01 a HLA class I allele; odds ratio [OR], 2.7; 95% confidence interval [CI], 1.9-3.8; P = 2.4 × 10-8) and with rs72631567 on chromosome 2 (OR, 2.0; 95% CI, 1.6-2.5; P = 9.7 × 10-9). The association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related DILI. The variant on chromosome 2 was associated with DILI from a variety of drugs. Further phenotypic analysis indicated that the association between DILI and A*33:01 was significant genome wide for cholestatic and mixed DILI, but not for hepatocellular DILI; the polymorphism on chromosome 2 was associated with cholestatic and mixed DILI as well as hepatocellular DILI. We identified an association between rs28521457 (within the lipopolysaccharide-responsive vesicle trafficking, beach and anchor containing gene) and only hepatocellular DILI (OR, 2.1; 95% CI, 1.6-2.7; P = 4.8 × 10-9). We did not associate any specific drug classes with genetic polymorphisms, except for statin-associated DILI, which was associated with rs116561224 on chromosome 18 (OR, 5.4; 95% CI, 3.0-9.5; P = 7.1 × 10-9). We validated the association between A*33:01 terbinafine- and sertraline-induced DILI. We could not validate the association between DILI and rs72631567, rs28521457, or rs116561224. CONCLUSIONS In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. We identified polymorphisms that appear to be associated with DILI from statins, as well as 2 non-drug-specific risk factors.

[1]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[2]  C. M. Cadwell,et al.  Cadherin tales: Regulation of cadherin function by endocytic membrane trafficking , 2016, Traffic.

[3]  S. Mallal,et al.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.

[4]  Masato Kimura,et al.  NCBI’s Database of Genotypes and Phenotypes: dbGaP , 2013, Nucleic Acids Res..

[5]  T. Morio,et al.  The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. , 2016, The Journal of allergy and clinical immunology.

[6]  R. Fontana,et al.  Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct , 2013 .

[7]  K. Urbánek,et al.  Acute cholestatic hepatitis induced by fenofibrate , 2009, Journal of clinical pharmacy and therapeutics.

[8]  T. Jaatinen,et al.  HLA antigen, allele and haplotype frequencies and their use in virtual panel reactive antigen calculations in the Finnish population. , 2013, Tissue antigens.

[9]  J. Benichou,et al.  Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen) , 2013, Drug Safety.

[10]  Imir G. Metushi,et al.  Treatment of PD‐1−/− mice with amodiaquine and anti‐CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients , 2015, Hepatology.

[11]  S. Lewitzky,et al.  OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis , 2010, Gut.

[12]  R. Andrade,et al.  Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. , 2006, World journal of gastroenterology.

[13]  A Floratos,et al.  Genome-wide association study of serious blistering skin rash caused by drugs , 2011, The Pharmacogenomics Journal.

[14]  A Jawaid,et al.  Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis , 2008, The Pharmacogenomics Journal.

[15]  B S Weir,et al.  HIBAG—HLA genotype imputation with attribute bagging , 2013, The Pharmacogenomics Journal.

[16]  Olivier Delaneau,et al.  Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel , 2014, Nature Communications.

[17]  M. Daly,et al.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. , 2011, Gastroenterology.

[18]  T. Santa,et al.  Ticlopidine, a Cholestatic Liver Injury-Inducible Drug, Causes Dysfunction of Bile Formation via Diminished Biliary Secretion of Phospholipids: Involvement of Biliary-Excreted Glutathione-Conjugated Ticlopidine Metabolites , 2013, Molecular Pharmacology.

[19]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[20]  A. Flahault,et al.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. , 1993, Journal of clinical epidemiology.

[21]  J. Sinclair,et al.  Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[22]  J. Cohen.  Primary Immunodeficiencies Associated with EBV Disease. , 2015, Current topics in microbiology and immunology.

[23]  K. Shianna,et al.  Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs , 2012, Pharmacogenetics and genomics.

[24]  B. Ludviksson,et al.  Risk of drug-induced liver injury from tumor necrosis factor antagonists. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  H. Takagi,et al.  Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study , 2008, The Pharmacogenomics Journal.

[26]  Michael Boehnke,et al.  LocusZoom: regional visualization of genome-wide association scan results , 2010, Bioinform..

[27]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[28]  D. Teachey.  Faculty Opinions recommendation of AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. , 2017 .

[29]  M. Lucena,et al.  Hepatitis aguda por ticlopidina. Presentación de 12 casos y revisión de la literatura , 2001 .

[30]  Evangelos Kalaitzakis,et al.  Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. , 2012, Journal of hepatology.

[31]  John Novembre,et al.  The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. , 2008, American journal of human genetics.

[32]  J. Hughes,et al.  Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy , 2015, Science.

[33]  O. Delaneau,et al.  Supplementary Information for ‘ Improved whole chromosome phasing for disease and population genetic studies ’ , 2012 .

[34]  Jae-Gook Shin,et al.  Multiple Cytochrome P450 Isoforms Are Involved in the Generation of a Pharmacologically Active Thiol Metabolite, whereas Paraoxonase 1 and Carboxylesterase 1 Catalyze the Formation of a Thiol Metabolite Isomer from Ticlopidine , 2014, Drug Metabolism and Disposition.

[35]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[36]  R. Andrade,et al.  Sertraline Hepatotoxicity: Report of a Case and Review of the Literature , 2010, Digestive Diseases and Sciences.

[37]  M. McCarthy,et al.  Casting a wider net for diabetes susceptibility genes , 2008, Nature Genetics.

[38]  S. Iverson,et al.  Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. , 2001, Chemical research in toxicology.

[39]  F. Rieux-Laucat,et al.  LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis. , 2016, Clinical immunology.

[40]  黒崎 真理子.  HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin , 2002 .

[41]  R. Boyapati,et al.  Acute liver injury secondary to sertraline , 2013, BMJ Case Reports.

[42]  M. Molokhia,et al.  Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury , 2011, Clinical pharmacology and therapeutics.

[43]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[44]  Z. Sthoeger,et al.  Ticlopidine-Induced Cholestatic Hepatitis , 2003, The Annals of pharmacotherapy.

[45]  A. J. Slater,et al.  Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01 , 2015, The Pharmacogenomics Journal.

[46]  Lei Guo,et al.  Sertraline induces endoplasmic reticulum stress in hepatic cells. , 2014, Toxicology.

[47]  S. Olafsson,et al.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. , 2013, Gastroenterology.

[48]  R. Andrade,et al.  [Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature]. , 2001, Revista de neurologia.

[49]  B. Lambrecht,et al.  Genes associated with common variable immunodeficiency: one diagnosis to rule them all? , 2016, Journal of Medical Genetics.

[50]  M. Pirmohamed,et al.  Characterization of amoxicillin‐ and clavulanic acid‐specific T cells in patients with amoxicillin‐clavulanate–induced liver injury , 2015, Hepatology.

[51]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[52]  G. Aithal,et al.  Genetic Basis of Drug-Induced Liver Injury: Present and Future , 2014, Seminars in Liver Disease.

[53]  E. Björnsson.  Drug-induced liver injury: an overview over the most critical compounds , 2015, Archives of Toxicology.

[54]  M. Pirmohamed,et al.  Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury , 2013, Hepatology.

[55]  K. Makar,et al.  Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo , 2012, Drug Metabolism and Disposition.

[56]  Yasunori Sato,et al.  Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. , 2010, Drug metabolism and pharmacokinetics.

[57]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[58]  B. Browning,et al.  Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. , 2007, American journal of human genetics.

[59]  D. Dhumeaux,et al.  Acute fatal hepatitis related to sertraline. , 2001, Journal of hepatology.

[60]  T. Fukami,et al.  Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. , 2010, Life sciences.

[61]  K. King,et al.  HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  James L Stevens,et al.  The future of drug safety testing: expanding the view and narrowing the focus. , 2009, Drug discovery today.

[63]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[64]  J. Spence,et al.  Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates) , 1998, Clinical pharmacokinetics.

[65]  M. Nelson,et al.  HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury , 2016, Pharmacogenetics and genomics.